Bavarian Nordic Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/5/2026)
| Balance Sheet | Total Assets | 14,954,537,000.00 | ROE | 86.06 % |
| Balance Sheet | Total Equity | 12,870,078,000.00 | ROA | 9.20 % |
| Cashflow | Capital Expenditures | -205,288,000.00 | P/FCF | 7.32 |
| Cashflow | Free Cash Flow | 2,516,615,000.00 | – | – |
| Cashflow | Operating Cash Flow | 2,721,903,000.00 | P/CF | 6.76 |
| Income | Earnings per Share (diluted) | 17.60 | Div. Yield | – |
| Income | Net Income | 1,375,378,000.00 | P/E | 13.39 |
| Income | Shares Outstanding | 78,269,900.00 | P/B | 1.43 |
| Income | Total Revenue | 6,171,025,000.00 | P/S | 2.98 |
Ratios calculated on: 10/14/2026
Company Description
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.bavarian-nordic.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more